AbbVie’s Chart Shows a Downward-Sloped Trend Despite Strong Fundamentals
Over the last six months, drug manufacturer AbbVie (NYSE: ABBV) has been confined to a downward trend with a channel defining the different cycles of the trend. The stock is near the upper rail of the channel at this point in time and the daily stochastic readings are in overbought territory.
As the channel has formed, the upper rail has developed from when the stochastic readings were in or near overbought territory. Given the current situation is showing such a scenario, it could be a sign that the stock is getting ready to get hit with another downswing.
From a fundamental perspective, AbbVie as a company has been performing far better than its stock would indicate. The company has averaged earnings growth of 19% per year over the last three years. The most recent quarter was even better with EPS growth of 52% over last year. Analysts expect overall earnings growth of 42% for this year as a whole.
In addition to the earnings growth, AbbVie has grown sales at a rate of 12% per year over the last three years and they grew by 18% in the most recent quarterly report.
The company has phenomenal profitability measurements with a return on equity of 185% currently and a profit margin of 39.4%.
This is a situation where the technical performance and the fundamental performance don’t match. If the stock can get through the resistance it faces, the fundamentals could help lift the stock over the next few quarters.
ABBV's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on June 23, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ABBV as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 50-day moving average for ABBV moved above the 200-day moving average on July 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in of 361 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ABBV broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (243.902) is very high in comparison to the industry average of (19.926). ABBV's P/E Ratio (123.892) is considerably higher than the industry average of (28.354). Projected Growth (PEG Ratio) (0.412) is also within normal values, averaging (3.932). Dividend Yield (0.027) settles around the average of (0.031) among similar stocks. P/S Ratio (7.138) is also within normal values, averaging (4.255).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement